National Advertising Division Recommends Good Life Discontinue Health Benefit and Personalization Claims for Compounded Tirzepatide+ Products

The National Advertising Division (NAD) recommended that Good Life Meds discontinue unsupported health benefit and personalization claims for its compounded Tirzepatide+ products following a challenge by Eli Lilly. NAD found that Good Life lacked reasonable basis for claims about weight loss, energy, blood sugar control, and lean muscle preservation, as well as overstated personalization claims. Good Life agreed to comply with the recommendations despite disagreeing with aspects of the decision.